aktuelle klinische Studien

ReActIF-ICE: Recovery from Acute Immune Failure in Septic Shock by Immune Cell Extracorporeal Therapy

Prospective, multicenter, randomized controlled parallel-group study

Subjects previously enrolled / randomized in the ReActIF-ICE (Recovery from acute immune failure in septic shock by immune cell extracorporeal terapy - immune competence enhancement) study received either standard sepsis treatment (control group) or standard sepsis treatment and additionally the ARTICE treatment (treatment group) during their index hospitalization. All subjects are followed up for 90 days after enrollment.

EXCHANGE 2

Randomized, prospective, multicenter, controlled study in a parallel group design to investigate the effectiveness of add-on plasma exchange therapy in septic shock – 2 (EXCHANGE-2)

Procyss

A prospective, randomized, multicenter, single-blind, controlled study to assess the performance of the cytosorb® 300 ml device for shock reversal in patients with vasoplegic septic shock

DIRE STRAITS

Diuretic Resistance-Strategies in Intensiv care- Albumin Transport Function as a Biomarker for Individualized Therapy in Diuretic-Unresponsive ICU Patients

Ausgezeichnet mit dem Dierichs-Stipendium der DGAI

Projektpartner: Europaweite Kollaboration mit Albunet, Fraunhofer IZI, MedInnovation Berlin

PerfusionLab

Modulare Ex-Vivo-Organperfusions-Plattform (Leber/Niere)

Förderung durch BMBF GoBio initial

Projektpartner: EXTHER Fraunhofer IZI, ASSESS MED, Dr. Ing. Andreas Körtge

HEMO-IE I

Hemoadsorption in Endocarditis - Pilot Study

Prospective, randomised, controlled, open-label, endpoint-blinded, single-centre PMCF to assess whether intraoperative CytoSorb® hemoadsorption reduces postoperative sepsis-related mortality and/or prolonged vasoplegic shock in high-risk patients with infective endocarditis.